Celltrion partners with US pharmacy chain for Yuflyma sales
Celltrion Healthcare, Celltrion's distribution unit, said Monday it has signed a deal with US specialty pharmacy chain CarePartners Pharmacy to sell its Humira biosimilar Yuflyma in the US market.
CarePartners Pharmacy is a national pharmacy that distributes medications across all 50 states and Washington DC, focusing on several niche programs, including autoimmune therapies.
Under the contract, Yuflyma will be distributed to drug stores operated by CarePartners Pharmacy nationwide, starting from the end of this month.
Celltrion said the partnership is expected to raise the presence of the Yuflyma autoimmune disease biosimilar among over 10 million patients in the US.
Yuflyma will be the only adalimumab sold at CarePartners Pharmacy drugstores as the US partner has decided not to sell AbbVie's blockbuster drug Humira and other competing biosimilars in the market.
Celltrion said it could ink the exclusive contract due to the drug's convenience both for patients and health care providers.
“Yuflyma uses a high concentration, citrate-free formulation, causing less pain when injected. The medication also comes with a latex-free injectable device, which can reduce allergy risk,” an official from Celltrion said.
Meanwhile, Celltrion Healthcare said the company will tap pharmacy benefit managers (PBMs), including Optum, to enlist Yuflyma in their formulary lists.
PBMs are companies that manage prescription drug benefits on behalf of health insurers. They negotiate fees and rebates with drug providers and create formulary lists of medications covered by insurance and reimburse pharmacies for patients' prescriptions.
Celltrion Healthcare said the company will increase its marketing efforts, with a goal of capturing around 40 percent share in the PBM market for adalimumab by the end of this year.
下一篇:Seoul shares open higher on US gains
相关文章:
- S. Korean diplomat discusses NK human rights with US envoy
- Over half of Koreans want continuous strengthening of alliance with US: poll
- Jakarta lights up in pink with SMTown Live 2023
- [Today’s K
- Seoul subway workers vote for strike plan
- SKC to build bioplastics plant in Vietnam
- Jakarta lights up in pink with SMTown Live 2023
- KFCC hosts UN conference for inclusive finance
- Over 1,300 rescue workers still traumatized by Itaewon Halloween tragedy
- Will Kep1er disband? Project group eyes extension with 'Magic Hour'
相关推荐:
- S. Korea, US, Japan install trilateral communication hotline amid N. Korea, China challenges
- [KH Explains] Lotte goes all
- [Herald Interview] Mimiirose hopes to make a name for itself
- [Herald Interview] Love is what defines artist Dawn
- Yoon lauds rapid growth of Korean defense industry
- [Herald Interview] Song Joong
- LG chief convenes CEO meeting to review growth strategy
- SK Earthon starts first independent oil production in South China Sea
- [Today’s K
- Reconstructed Dondeokjeon hall in Deoksu Palace to open to public
- S. Korean diplomat discusses NK human rights with US envoy
- Welcome Daehakro Festival lights up Seoul's stage hub
- USS Carl Vinson deploys for Indo
- Another suspect of Tajik duo behind S. Korean money exchange robbery nabbed
- HiteJinro to produce soju in Vietnam
- Seoul subway workers vote for strike plan
- TvN Sports, CGV to screen Bundesliga’s first ‘Korean derby’
- S.Korea's largest
- [view] 민심 더 싸늘해지는데…감동 없는 김기현 2기
- USS Carl Vinson deploys for Indo
- 반도핑기구 “아시안게임 북 인공기 게양에 조치 취할 것”
- Show must go on: 28th Busan International Film Festival kicks off despite setbacks
- [Our Museums] Journey to the Paleolithic era at Jeongok Prehistory Museum
- Apple under fire for ‘overpriced’ iPhones
- Questions raised over Taihan Cable’s quality control
- Where is Blackpink headed?
- Hyundai Glovis to go net